Calytrix Bio Enters An Agreement To Be Acquired By Lilly
Nov 16 (Reuters) - Eli Lilly and Company LLY.N:
CALYTRIX BIO ENTERS AN AGREEMENT TO BE ACQUIRED BY LILLY TO ADVANCE OUTCOMES FOR PATIENTS LIVING WITH ESSENTIAL THROMBOCYTHEMIA AND MYELOFIBROSIS
CALYTRIX BIO: LILLY WILL ACQUIRE CALYTRIX, AND CALYTRIX SHAREHOLDERS COULD RECEIVE UP TO $1.5 BILLION IN CASH
Further company coverage: LLY.N